nach oben

Annals of Hematology

Erschienen in:

01.06.2012 | Original Article

Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells

verfasst von: Jing Zou, Ping Zou, Jie Wang, Lei Li, Yong Wang, Daohong Zhou, Lingbo Liu

Erschienen in: Annals of Hematology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Ex vivo expansion of hematopoietic stem cells (HSCs) depends on HSC self-renewing proliferation and functional maintenance, which can be negatively affected by HSC differentiation, apoptosis, and senescence. Therefore, inhibition of HSC senescence may promote HSC expansion. To test this hypothesis, we examined the effect of inhibition of p38 mitogen-activated protein kinase (p38) on the expansion of human umbilical cord blood (hUCB) CD133⁺ cells because activation of p38 has been implicated in the induction of HSC senescence under various physiological and pathological conditions. Our results showed that ex vivo expansion of hUCB CD133⁺ cells activated p38, which was abrogated by the p38 specific inhibitor SB203580 (SB). Inhibition of p38 activity with SB promoted the expansion of CD133⁺ cells and CD133⁺CD38⁻ cells. In addition, hUCB CD133⁺ cells expanded in the presence of SB for 7 days showed about threefold increase in the clonogenic function of HSCs and engraftment in non-obese diabetic/severe combined immunodeficient mice after transplantation compared to the input cells. In contrast, the cells expanded without SB exhibited a significant reduction in these HSC functions. The enhancement of ex vivo expansion of hUCB HSCs is primarily attributable to SB-mediated inhibition of HSC senescence. In addition, inhibition of HSC apoptosis and upregulation of CXCR4 may also contribute to the enhancement. However, p38 inhibition had no significant effect on HSC differentiation and proliferation. These findings suggest that inhibition of p38 activation may represent a novel strategy to promote ex vivo expansion of hUCB HSCs.

Kelly SS, Sola CB, de Lima M, Shpall E (2009) Ex vivo expansion of cord blood. Bone Marrow Transplant 44:673–681PubMedCrossRef

Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW, Takahashi TA, Ortega J, Filipovich A, Locatelli F, Asano S, Fagioli F, Vowels M, Sirvent A, Laporte JP, Tiedemann K, Amadori S, Abecassis M, Bordigoni P, Diez B, Shaw PJ, Vora A, Caniglia M, Garnier F, Ionescu I, Garcia J, Koegler G, Rebulla P, Chevret S (2004) Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 32:397–407PubMedCrossRef

Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK (2002) Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 8:368–376PubMedCrossRef

Peffault DLR, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V, Maury S, Kurtzberg J, Bonfim C, Aljurf M, Gluckman E, Socie G, Passweg J, Rocha V (2011) Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 17:78–85CrossRef

Devine SM, Lazarus HM, Emerson SG (2003) Clinical application of hematopoietic progenitor cell expansion: current status and future prospects. Bone Marrow Transplant 31:241–252PubMedCrossRef

Geest CR, Coffer PJ (2009) MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 86:237–250PubMedCrossRef

Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838–2849PubMedCrossRef

Zarubin T, Han J (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res 15:11–18PubMedCrossRef

Wang Y, Liu L, Zhou D (2011) Inhibition of p38 MAPK attenuates ionizing radiation-induced hematopoietic cell senescence and residual bone marrow injury. Radiat Res 176:743–752PubMedCrossRef

10.

Somervaille TC, Linch DC, Khwaja A (2003) Different levels of p38 MAP kinase activity mediate distinct biological effects in primary human erythroid progenitors. Br J Haematol 120:876–886PubMedCrossRef

11.

Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P, Balasubramanian L, Parmar S, Varga J, Tallman MS, Verma A, Platanias LC (2005) Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 65:9029–9037PubMedCrossRef

12.

Saadatzadeh MR, Bijangi-Vishehsaraei K, Kapur R, Haneline LS (2009) Distinct roles of stress-activated protein kinases in Fanconi anemia-type C-deficient hematopoiesis. Blood 113:2655–2660PubMedCrossRef

13.

Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, Matsuoka S, Miyamoto T, Ito K, Ohmura M, Chen C, Hosokawa K, Nakauchi H, Nakayama K, Nakayama KI, Harada M, Motoyama N, Suda T, Hirao A (2007) Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1:101–112PubMedCrossRef

14.

Iiyama M, Kakihana K, Kurosu T, Miura O (2006) Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. Cell Signal 18:174–182PubMedCrossRef

15.

Shao L, Li H, Pazhanisamy SK, Meng A, Wang Y, Zhou D (2011) Reactive oxygen species and hematopoietic stem cell senescence. Int J Hematol 94:24–32PubMedCrossRef

16.

Ivanovic Z, Dello SP, Trimoreau F, Faucher JL, Praloran V (2000) Primitive human HPCs are better maintained and expanded in vitro at 1 percent oxygen than at 20 percent. Transfusion 40:1482–1488PubMedCrossRef

17.

Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, Platanias LC (2002) Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 277:7726–7735PubMedCrossRef

18.

Nagata Y, Moriguchi T, Nishida E, Todokoro K (1997) Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 90:929–934PubMed

19.

Wang Y, Kellner J, Liu L, Zhou D (2011) Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion. Stem Cells Dev 20:1143–1152PubMedCrossRef

20.

Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:1345–1348PubMedCrossRef

21.

Alakel N, Jing D, Muller K, Bornhauser M, Ehninger G, Ordemann R (2009) Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. Exp Hematol 37:504–513PubMedCrossRef

22.

Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, Gilliland DG (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325–339PubMedCrossRef

23.

Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N (2007) Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood 109:3570–3578PubMedCrossRef

24.

Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Et A (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363–9367PubMedCrossRef

25.

Wang Y, Schulte BA, LaRue AC, Ogawa M, Zhou D (2006) Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 107:358–366PubMedCrossRef

26.

Yao CL, Feng YH, Lin XZ, Chu IM, Hsieh TB, Hwang SM (2006) Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133(+) cells. Stem Cells Dev 15:70–78PubMedCrossRef

27.

Araki H, Baluchamy S, Yoshinaga K, Petro B, Petiwala S, Parajuli R, Milhem M, Lavelle D, DeSimone J, Mahmud N (2009) Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues. Exp Hematol 37:1084–1095PubMedCrossRef

28.

Sauvageau G, Iscove NN, Humphries RK (2004) In vitro and in vivo expansion of hematopoietic stem cells. Oncogene 23:7223–7232PubMedCrossRef

29.

Hofmeister CC, Zhang J, Knight KL, Le P, Stiff PJ (2007) Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant 39:11–23PubMedCrossRef

30.

Attar EC, Scadden DT (2004) Regulation of hematopoietic stem cell growth. Leukemia 18:1760–1768PubMedCrossRef

31.

Ono K, Han J (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12:1–13PubMedCrossRef

32.

Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y, Suda T (2006) Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12:446–451PubMedCrossRef

33.

Stein GH, Drullinger LF, Soulard A, Dulic V (1999) Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19:2109–2117PubMed

34.

Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22:4212–4222PubMedCrossRef

35.

Akala OO, Clarke MF (2006) Hematopoietic stem cell self-renewal. Curr Opin Genet Dev 16:496–501PubMedCrossRef

36.

Dahlberg A, Delaney C, Bernstein ID (2011) Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 117:6083–6090PubMedCrossRef

37.

Cirillo PF, Pargellis C, Regan J (2002) The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem 2:1021–1035PubMedCrossRef

38.

Zou J, Zou P, Lou Y, Xiao Y, Wang J, Liu L (2011) The cross-talk between ROS and p38MAPKα in the ex vivo expanded human umbilical cord blood CD133(+) cells. J Huazhong Univ Sci Technol Med Sci 31:591–595PubMedCrossRef

39.

Baudet A, Larsson J (2011) A forward RNAi screen identifies p38 MAP kinase as a druggable target for expansion of human hematopoietic stem cells. Blood 118(No. 21):1016, abstract #2352

40.

Sauvageau G, Humphries RK (2010) Medicine. The blood stem cell Holy Grail? Science 329:1291–1292PubMedCrossRef

41.

Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845–848PubMedCrossRef

42.

Lapidot T, Kollet O (2002) The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16:1992–2003PubMedCrossRef

43.

Mobest D, Goan SR, Junghahn I, Winkler J, Fichtner I, Hermann M, Becker M, de Lima-Hahn E, Henschler R (1999) Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells. Stem Cells 17:152–161PubMedCrossRef

Titel: Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells
verfasst von: Jing Zou
Ping Zou
Jie Wang
Lei Li
Yong Wang
Daohong Zhou
Lingbo Liu
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 6/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-011-1397-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Follicular lymphoma with prominent fibrosis complicated by peripheral eosinophilia

Ferroportin (SLC40A1) Q248H mutation is associated with lower circulating serum hepcidin levels in Rwandese HIV-positive women

Mild hepatic iron overload in dysmetabolic hyperferritinemia: MRI may overestimate the liver iron concentration values

Vincristine-induced vocal cord paralysis in a patient with acute lymphoblastic leukemia

Successful transfusion care for a patient with the Rhesus -D- phenotype and antibodies against Rh17 and two additional alloantibodies